Literature DB >> 30029059

Myeloid-derived suppressor cells exacerbate Sjögren's syndrome by inhibiting Th2 immune responses.

Jingjing Qi1, Dan Li1, Guoping Shi1, Xuefang Zhang1, Yuchen Pan1, Huan Dou2, Genhong Yao3, Yayi Hou4.   

Abstract

Myeloid-derived suppressor cells (MDSCs) can regulate various aspects of immune responses based on their potent immune-suppressive activity. Studies reported that MDSCs participated in many autoimmune diseases. However, the role of MDSCs in Sjögren's syndrome (SS) is unknown. In this study, we determined the frequencies and function of MDSCs in non-obese diabetic (NOD) mice and SS patients. The NOD mice were adoptively transferred with MDSCs or treated with anti-Gr1 antibody. Results showed that peripheral MDSCs increased significantly with the development of SS-like syndrome in NOD mice and the percentage of MDSCs was higher in SS patients than healthy controls. The SS-like syndrome aggravated after transfer of MDSCs in NOD mice. The deletion of MDSCs in NOD mice alleviated SS-like syndrome. Mechanistically, MDSCs down-regulated the percentages of Th2 cells in NOD mice and SS patients. In summary, our findings suggested that MDSCs exacerbated Sjögren's syndrome by inhibiting Th2 cells.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Myeloid-derived suppressor cells; Sjögren’s syndrome; Th2 cells

Mesh:

Year:  2018        PMID: 30029059     DOI: 10.1016/j.molimm.2018.07.016

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

Review 1.  Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.

Authors:  Jilu Zhang; Alan Hodges; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cell Immunol       Date:  2021-02-04       Impact factor: 4.868

2.  Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2/PGE2 in experimental sialadenitis.

Authors:  Jingjing Qi; Xiaojun Tang; Wenchao Li; Weiwei Chen; Genhong Yao; Lingyun Sun
Journal:  Stem Cell Res Ther       Date:  2020-07-29       Impact factor: 6.832

3.  Interleukin‑12 exacerbates Sjögren's syndrome through induction of myeloid‑derived suppressor cells.

Authors:  Jingjing Qi; Dan Li; Guoping Shi; Xuefang Zhang; Yuchen Pan; Huan Dou; Tingting Wang; Genhong Yao; Yayi Hou
Journal:  Mol Med Rep       Date:  2019-06-06       Impact factor: 2.952

Review 4.  T Cells Subsets in the Immunopathology and Treatment of Sjogren's Syndrome.

Authors:  William de Jesús Ríos-Ríos; Sorely Adelina Sosa-Luis; Honorio Torres-Aguilar
Journal:  Biomolecules       Date:  2020-11-11

Review 5.  Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases.

Authors:  Youngjae Park; Seung-Ki Kwok
Journal:  Immune Netw       Date:  2022-02-11       Impact factor: 5.851

6.  Therapeutic effect of modified zengye decoction on primary Sjogren's syndrome and its effect on plasma exosomal proteins.

Authors:  Yimin Zeng; Xin Peng; Yun Wang; Lei Hou; Wukai Ma; Peng Yang
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

7.  Myeloid-Derived Suppressor Cells Promote the Progression of Primary Membranous Nephropathy by Enhancing Th17 Response.

Authors:  Huimin Li; Hao Wu; Qiaoyan Guo; Hongyu Yu; Ying Xu; Jinyu Yu; Zhongkun Wang; Huanfa Yi
Journal:  Front Immunol       Date:  2020-08-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.